{"id":30883,"date":"2025-09-22T19:03:59","date_gmt":"2025-09-22T13:33:59","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30883"},"modified":"2026-03-20T17:42:32","modified_gmt":"2026-03-20T12:12:32","slug":"future-of-multiple-system-atrophy-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment","title":{"rendered":"The Future of Multiple System Atrophy Treatment: Pioneering Approaches Beyond Levodopa Reliance"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f4ce93600c2\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f4ce93600c2\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment\/#Current_Therapeutic_Approaches_to_Autonomic_Dysfunction_in_Multiple_System_Atrophy_MSA\" >Current Therapeutic Approaches to Autonomic Dysfunction in Multiple System Atrophy (MSA)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment\/#Reliance_on_Levodopa\" >Reliance on Levodopa<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment\/#A_New_Era_of_Alpha-Synuclein_in_Multiple_System_Atrophy_Treatment\" >A New Era of Alpha-Synuclein in Multiple System Atrophy Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment\/#Bridging_the_Gap_Between_Symptom_Control_and_Disease_Progression\" >Bridging the Gap Between Symptom Control and Disease Progression<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment\/#Future_Prospects\" >Future Prospects<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Multiple system atrophy (MSA) is a rare and progressive neurodegenerative disorder that affects the autonomic nervous system, motor function, and balance. Multiple system atrophy symptoms manifests through a combination of parkinsonism, autonomic dysfunction, and cerebellar ataxia, making it distinct from Parkinson\u2019s disease despite overlapping symptoms. Unlike Parkinson\u2019s, MSA progresses rapidly, and available treatments focus mainly on symptom relief rather than addressing the root causes of the disease, leaving significant unmet medical needs.&nbsp;<\/p>\n\n\n\n<p>As per DelveInsight\u2019s analysis, more than <strong>70K<\/strong> people across the seven major markets (the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan) were <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-epidemiology-forecast\">diagnosed with MSA<\/a> in 2024, with <strong>the US<\/strong> accounting for approximately <strong>60%<\/strong> of the cases, highlighting the need for accelerated research and therapeutic innovation.<\/p>\n\n\n\n<p>Multiple System Atrophy (MSA) manifests in two principal subtypes, MSA-P (parkinsonian) and MSA-C (cerebellar), each influencing the msa disease progression stages in distinct ways. MSA-P is characterized by rigidity, bradykinesia, and tremors that closely resemble Parkinson\u2019s disease, often complicating early and accurate diagnosis. As the disease advances, patients may experience worsening motor impairment alongside autonomic dysfunction, including orthostatic hypotension and urinary disturbances.<\/p>\n\n\n\n<p>In contrast, MSA-C predominantly affects balance and coordination, presenting as cerebellar ataxia, gait instability, and speech difficulties. These symptoms tend to drive a different trajectory within the msa disease progression stages, with earlier impairment in mobility and coordination. Across both subtypes, progression is typically rapid, marked by increasing disability, reduced independence, and significant impact on quality of life, underscoring the need for timely recognition and comprehensive management strategies.<\/p>\n\n\n\n<p>Additionally, it is noteworthy that in the <strong>US<\/strong> and <strong>European<\/strong> countries, including Germany, France, Italy, Spain, and the United Kingdom, an average of <strong>70%<\/strong> of patients are diagnosed with <strong>MSA-P,<\/strong> while <strong>30%<\/strong> have <strong>MSA-C.<\/strong> In contrast, <strong>Japan<\/strong> shows a different distribution, with <strong>30%<\/strong> of cases being <strong>MSA-P<\/strong> and <strong>70% MSA-C<\/strong>, possibly due to regional differences in disease expression and genetic factors.<\/p>\n\n\n\n<p>Furthermore, MSA disease progresses through various stages, from Stage 1 to Stage 5, with <strong>Stages 3\u20134<\/strong> accounting for nearly <strong>70%<\/strong> of cases. This stage-specific data highlights the need for targeted treatments tailored to the disease&#8217;s progression.<\/p>\n\n\n\n<p>To address both early and late-stage MSA, <strong>Alterity Therapeutics<\/strong> is bringing a novel molecule to the market. <strong>ATH434<\/strong>, a promising <strong>disease-modifying therapy (DMT)<\/strong> in development, is designed to address both <strong>early <\/strong>and<strong> late-stage MSA<\/strong>, aligning with this need.&nbsp;<\/p>\n\n\n\n<p>The hallmark of MSA is the abnormal accumulation of alpha-synuclein in oligodendrocytes, which is thought to drive widespread cell loss in the brain. Despite this critical insight, the market still lacks an <a href=\"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment\">approved treatment for MSA<\/a>. While significant progress has been made in experimental therapies targeting alpha-synuclein aggregation, these therapies are yet to translate into a widely accpeted solution. This raises the question:&nbsp;<\/p>\n\n\n\n<p><em>Why has an effective alpha-synuclein-targeting drug not yet reached the market? Is it the complexity of the disease\u2019s pathology, the challenges in clinical trials, or are there other unforeseen barriers preventing approval?<\/em><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"377\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161208\/Multiple-System-Atrophy-Market-Key-Insights-1024x377.png\" alt=\"Multiple-System-Atrophy-Market-Key-Insights\" class=\"wp-image-30888\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161208\/Multiple-System-Atrophy-Market-Key-Insights-1024x377.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161208\/Multiple-System-Atrophy-Market-Key-Insights-300x111.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161208\/Multiple-System-Atrophy-Market-Key-Insights-150x55.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161208\/Multiple-System-Atrophy-Market-Key-Insights-768x283.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161208\/Multiple-System-Atrophy-Market-Key-Insights-1536x566.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161208\/Multiple-System-Atrophy-Market-Key-Insights-2048x754.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-therapeutic-approaches-to-autonomic-dysfunction-in-multiple-system-atrophy-msa\"><span class=\"ez-toc-section\" id=\"Current_Therapeutic_Approaches_to_Autonomic_Dysfunction_in_Multiple_System_Atrophy_MSA\"><\/span><strong>Current Therapeutic Approaches to Autonomic Dysfunction in Multiple System Atrophy (MSA)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In the ongoing battle against MSA, the current market is brimming with off-label therapies and generic drugs, none of which are explicitly authorized for the condition. This glaring gap underscores the pressing need for a treatment capable of effectively managing or halting the disease\u2019s progression.&nbsp;<\/p>\n\n\n\n<p>Symptomatic management remains the cornerstone of MSA care, as no disease-modifying medication has proven effective in halting its progression. Managing MSA involves addressing a range of debilitating symptoms through tailored treatments. For MSA-P treatment or <a href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapeutic-market\">parkinsonism<\/a>, first-line therapy includes levodopa combined with domperidone and physiotherapy, while alternatives like dopamine agonists or amantadine may be considered. MSA-C treatment primarily relies on physiotherapy, supplemented by medications such as clonazepam or gabapentin. Nonpharmacological measures and adrenergic receptor agonists like midodrine are standard for orthostatic hypotension, with alternatives like fludrocortisone or droxidopa for severe cases.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s forecast model, in 2024, <strong>adrenergic receptor agonists<\/strong> generated the highest revenue of approximately <strong>USD 30 million <\/strong>in 7MM. Furthermore, the<a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-market\"> multiple system atrophy treatment market<\/a> is expected to increase at a significant CAGR by 2034 due to the expected entry of emerging molecules.<\/p>\n\n\n\n<p>However, to date, there is no cure for MSA, and no treatment exists that can stop or reverse the course of MSA. Nevertheless, over the past decade, research in preclinical models and patients has advanced the understanding of the disease\u2019s underlying pathophysiological mechanisms. While the precise cause of MSA remains unclear, it is believed to be multifactorial, involving a combination of triggers that may serve as potential targets for novel therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Reliance_on_Levodopa\"><\/span><strong>Reliance on Levodopa<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>\u201c<\/strong><em>MSA is not as benign a disease as Parkinson&#8217;s disease, and it does not respond to the same treatments. It is essential to diagnose early.<\/em><\/p>\n<cite>&#8211; <strong>Chief Executive Officer and Cofounder, Amprion<\/strong><\/cite><\/blockquote>\n\n\n\n<p>For more than a decade, the market has heavily relied on levodopa for the treatment of MSA-P, reflecting a heavy dependence on this decades-old therapy. Despite its limited and often transient effectiveness in MSA compared to Parkinson\u2019s disease, levodopa is widely prescribed. Its efficacy in alleviating bradykinesia and rigidity provides temporary relief, but as MSA progresses rapidly, many patients experience diminishing benefits.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Our analyst&#8217;s findings, corroborated by key opinion leaders, revealed that levodopa remains <strong>the most prescribed drug<\/strong> for MSA patients, accounting for nearly <strong>30%<\/strong> of the total multiple system atrophy treatment market size in the 7MM in 2023. This highlights the ongoing reliance on this treatment due to the absence of disease-modifying options.<\/p>\n\n\n\n<p>The increasing demand for innovative treatments underscores the pressing need to develop targeted strategies beyond levodopa for holistic management of MSA.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cSeverely debilitating illnesses lacking treatments offer opportunities for new entrants addressing the disease\u2019s root cause.\u201d<\/em><\/p>\n<cite>&#8211; <strong>Neurologist, University of California, Irvine<\/strong><\/cite><\/blockquote>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"A_New_Era_of_Alpha-Synuclein_in_Multiple_System_Atrophy_Treatment\"><\/span><strong>A New Era of Alpha-Synuclein in Multiple System Atrophy Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Alpha-synuclein, a protein primarily found in presynaptic terminals, has emerged as a pivotal target in the search for disease-modifying treatments (DMTs) for MSA. While its normal function involves neurotransmitter release and synaptic plasticity, its misfolding, aggregation, and prion-like spread across the brain are central to the progression of synucleinopathies. Recent research has shown that alpha-synuclein oligomers, rather than large fibrillar aggregates, are the primary neurotoxic species, driving neuronal dysfunction and damage.&nbsp;<\/p>\n\n\n\n<p>This discovery has opened the door to <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-pipeline-insight\">innovative therapeutic strategies for MSA treatment<\/a> aimed at preventing or reversing alpha-synuclein aggregation. Some promising developments in multiple system atrophy clinical trials include <strong>Amlenetug (currently in Phase III), TAK-341\/MEDI1341 (Phase II), Emrusolmin (Phase II), <\/strong>and<strong> ATH434 (Phase II)<\/strong>. Notably, Amlenetug has demonstrated its ability to inhibit the seeding of alpha-synuclein by binding to these aggregates. Additionally, the promising preclinical results of Emrusolmin further strengthen the case for alpha-synuclein inhibitors as a potential therapeutic avenue.<\/p>\n\n\n\n<p>These findings highlight the potential of targeting alpha-synuclein as a key therapeutic pathway, offering hope for novel treatments that could modify the disease course in MSA patients and alleviate their symptoms.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td colspan=\"5\"><strong>Key Pipeline Assets of Alpha-Synuclein Inhibitors in the Multiple System Atrophy Market<\/strong><\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td><strong>Company<\/strong><\/td><td><strong>Phase<\/strong><\/td><td><strong>Route of Administration (RoA)<\/strong><\/td><td><strong>Estimated Market Entry in the US<\/strong><\/td><\/tr><tr><td><strong>Amlenetug<\/strong><strong>(Lu AF82422)<\/strong><\/td><td>H. Lundbeck\/ Genmab<\/td><td>III<\/td><td>Intravenous (IV)<\/td><td>2029<\/td><\/tr><tr><td><strong>TAK-341\/ MEDI1341<\/strong><\/td><td>AstraZeneca\/ Takeda Pharma<\/td><td>II<\/td><td>IV infusion<\/td><td>2030<\/td><\/tr><tr><td><strong>Emrusolmin (TEV-56286)<\/strong><\/td><td>Teva Pharmaceutical\/&nbsp; MODAG<\/td><td>II<\/td><td>Oral<\/td><td>2032<\/td><\/tr><tr><td><strong>ATH434<\/strong><\/td><td>Alterity Therapeutics<\/td><td>II<\/td><td>Oral<\/td><td>2030<\/td><\/tr><tr><td colspan=\"5\">These numbers are based on Primary Completion Date (PCD) from ClinicalTrials.gov along with our internal assumptions.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bridging_the_Gap_Between_Symptom_Control_and_Disease_Progression\"><\/span><strong>Bridging the Gap Between Symptom Control and Disease Progression<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Amlenetug (Lu AF82422),<\/strong> the anticipated <strong>first disease-modifying treatment (DMT) <\/strong>&nbsp;for MSA according to Lundbeck&#8217;s latest reports, is a monoclonal antibody targeting alpha-synuclein. It has garnered attention from the US FDA, EMA, and Japanese health authorities. This multiple system atrophy treatment drug has received several designations enhancing its clinical pathway for approval, including <strong>Orphan Drug Designation (ODD)<\/strong> from both the US FDA and EMA, Fast Track Designation (FTD) from the FDA, and with <strong>SAKIGAKE designation<\/strong> in Japan, further boosting its profile in the fight against MSA.<\/p>\n\n\n\n<p>The encouraging findings from the Phase II trial showed a 19% reduction in clinical progression (measured by the UMSARS total score), but the results were not statistically significant. Nevertheless, deeper analysis revealed more consistent, promising reductions in disease progression across subscales, highlighting a potential therapeutic pathway. As the AMULET study progresses, it offers hope for more targeted <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-pipeline-insight\">therapies for MSA<\/a>, marking a critical step in addressing the unmet needs of this devastating condition.<\/p>\n\n\n\n<p>Theravance Biopharma\u2019s Phase III molecule is also in the race as a symptomatic MSA treatment. <strong>Ampreloxetine<\/strong>, an investigational norepinephrine reuptake inhibitor, is being developed to treat symptomatic neurogenic orthostatic hypotension in patients with MSA. The drug functions by binding to norepinephrine transporters, thereby increasing extracellular norepinephrine levels. The <strong>ODD<\/strong> granted by the US FDA underscores its potential for addressing this rare condition.<\/p>\n\n\n\n<p>Although Ampreloxetine faced a setback when its Phase III, <strong>REDWOOD<\/strong> trial was terminated based on efficacy results, the company remains optimistic and has initiated another Phase III trial, called <strong>CYPRESS<\/strong>, following discussion with the FDA. Full enrollment in August 2025 sets the stage for topline data readout anticipated in the first quarter of 2026, with expedited New Drug Application (NDA) and priority FDA review strategies underscoring the potential in MSA symptom management. If approved, Ampreloxetine could become the first-in-class, durable, and convenient treatment for multiple system atrophy\u2013related neurogenic orthostatic hypotension, competing with existing options such as droxidopa and midodrine.<\/p>\n\n\n\n<p>Moreover, Alterity Therapeutics\u2019 ATH434, which also holds ODD in MSA, demonstrated promising clinical and biomarker outcomes in the 12-month ATH434-202 Phase II trial reported in July 2025. UMSARS I scores increased 3.5 points versus 6.5 historically, with 43% of participants stable and 30% improved on global impression scales. Orthostatic hypotension symptoms remained stable, while biomarker analyses indicated slowed brain atrophy, reduced iron accumulation in the basal ganglia, and stable plasma and <strong>cerebrospinal fluid (CSF)<\/strong> neurofilament light chain, demonstrating target engagement. ATH434\u2019s favorable safety profile supports continued development as a potential disease-modifying therapy for both early and advanced MSA.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_Prospects\"><\/span><strong>Future Prospects<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The future of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-market\">MSA market<\/a> is poised for transformation, driven by the increasing recognition of disease-modifying therapies and a focus on innovative treatment modalities. Research into the pathophysiology of MSA, especially the role of alpha-synuclein aggregation, is opening up new therapeutic avenues. Current efforts focus on both managing MSA symptoms and pursuing a potential cure for MSA.&nbsp;<\/p>\n\n\n\n<p>The dynamic MSA drug landscape, with multiple competitors developing innovative therapies, signals a shift toward more targeted, disease-modifying approaches. Several companies are advancing novel drug candidates, such as <strong>Amlenetug (Lu af82422), Ampreloxetine, TAK-341\/MEDI1341,<\/strong> <strong>Emrusolmin (TEV-56286),<\/strong> and <strong>ATH434<\/strong>, among other candidates which have the potential to address unmet needs. Industry leaders like <strong>H. Lundbeck, Genmab,<\/strong> <strong>Theravance Biopharma, AstraZeneca, Takeda Pharma, Teva Pharmaceutical, MODAG GmbH, <\/strong>and <strong>Alterity Therapeutics, <\/strong>among others, are poised to lead the market. As these treatments advance, the market is expected to experience substantial growth, with emerging therapies likely to increase market value significantly by 2034. The future lies in precision medicine and therapies tailored to MSA\u2019s complex mechanisms.&nbsp;<\/p>\n\n\n\n<p>Among the leading <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-pipeline-insight\">multiple system atrophy treatment drug candidates<\/a> in development, <strong>Amlenetug<\/strong> is projected to capture the <strong>highest<\/strong> market share by 2034, as it is anticipated to be the first entrant in the market. This success is largely attributed to its strong safety and efficacy profile.<\/p>\n\n\n\n<p>In addition, several promising novel molecules are in mid-stage development. <strong>ATH434, <\/strong>an alpha-synuclein inhibitor, is expected to secure approximately <strong>30%<\/strong> of the total MSA market across the 7 major markets (United States, Germany, France, Italy, Spain, the United Kingdom, and Japan),&nbsp; by 2034.&nbsp;<\/p>\n\n\n\n<p>Furthermore, early identification of MSA using biofluid and neuroimaging biomarkers is critical, as patterns of iron accumulation differ markedly from Parkinson\u2019s disease. However, challenges persist in defining \u2018early\u2019 MSA, which remains a somewhat fluid concept. Biomarkers such as neurofilament light are gaining prominence in improving diagnostic accuracy and refining patient selection for clinical trials.&nbsp;<\/p>\n\n\n\n<p>Insights from ongoing assessments, like those involving ATH434, underscore the potential of these markers to detect iron accumulation in specific brain regions, advancing both early diagnosis and the development of targeted therapeutic approaches. These advancements aim to enhance the precision and efficacy of MSA clinical research and management strategies. This analysis is further supported by the key leaders who have shown a blend of excitement and measured optimism regarding MSA.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201c<em>A lot of times patients come in with a Parkinson\u2019s disease diagnosis, they may have a couple of red flags that make you think, \u2018Oh, this is not like a run-of-the-mill patient with Parkinson, and that might or might not be MSA&#8230;\u2019 What we really are trying to do is come up with biofluid and neuroimaging biomarkers that help us get a better sense if this patient really has what we think is an MSA diagnosis.\u201d<\/em><\/p>\n<cite>&#8211; <strong>Director, Huntington\u2019s Disease Clinic, Vanderbilt University<\/strong><\/cite><\/blockquote>\n\n\n\n<p>A comprehensive assessment of emerging drug assets in the MSA treatment pipeline, along with detailed analyses, is available in the final report provided by DelveInsight. Multiple system atrophy competitive analysis underscores growing innovation, with companies targeting both early- and late-stage MSA, reflecting a shift toward precision, disease-modifying treatment strategies. The report also covers anticipated drug candidates, projected launch timelines, and provides in-depth analytical insights into each asset\u2019s potential market impact.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-1024x194.png\" alt=\"Multiple System Atrophy Market Outlook and Assessment\" class=\"wp-image-30887\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span>FAQs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1757479279647\"><strong class=\"schema-faq-question\"><strong><strong>What is Multiple System Atrophy (MSA)disease?<\/strong><\/strong><\/strong> <p class=\"schema-faq-answer\">MSA is a rare, progressive neurodegenerative disorder that affects the autonomic nervous system, motor function, and balance. It triggers symptoms such as parkinsonism (rigidity, tremors), cerebellar ataxia (coordination and balance problems), and autonomic dysfunction (orthostatic hypotension, bladder, and bowel issues).<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757479289074\"><strong class=\"schema-faq-question\"><strong>What causes MSA?<\/strong><\/strong> <p class=\"schema-faq-answer\">MSA is caused by abnormal accumulation of alpha-synuclein in oligodendrocytes, leading to neuronal degeneration across the brain and spinal cord. Its exact cause remains unclear, but it is considered multifactorial, involving a combination of genetic susceptibility, environmental triggers, and cellular mechanisms that disrupt normal brain function.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757479303962\"><strong class=\"schema-faq-question\"><strong>How many stages of MSA are there?<\/strong><\/strong> <p class=\"schema-faq-answer\">MSA progresses through five stages, from early mild symptoms (Stage 1) to severe disability (Stage 5). Stages 3 and 4 account for the majority of patients, marked by significant motor impairment, autonomic dysfunction, and increased dependency. Understanding disease stage is critical for treatment selection and prognosis assessment.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757479314436\"><strong class=\"schema-faq-question\"><strong>What are the first signs of MSA?<\/strong><\/strong> <p class=\"schema-faq-answer\">Early signs of MSA include autonomic dysfunction, such as low blood pressure when standing, urinary incontinence, or erectile dysfunction. Motor symptoms like rigidity, slowness, tremors, and gait instability may also appear. Cerebellar signs like balance problems or coordination difficulties can be early indicators, especially in the MSA-C subtype.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758540797101\"><strong class=\"schema-faq-question\">Is MSA hereditary?<\/strong> <p class=\"schema-faq-answer\">MSA is generally considered a sporadic condition, meaning it typically occurs without a family history. Rare familial cases have been reported, suggesting some genetic predisposition may exist. However, inherited patterns are uncommon, and most patients develop the disease due to complex interactions between genetic and environmental factors rather than direct inheritance.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758540811989\"><strong class=\"schema-faq-question\">How is MSA treated?<\/strong> <p class=\"schema-faq-answer\">Treatment focuses on symptom management, as no disease-modifying therapy is approved. Levodopa may relieve parkinsonian symptoms, physiotherapy supports mobility, and adrenergic agents like midodrine or droxidopa address orthostatic hypotension. Emerging therapies, such as ATH434 and ampreloxetine, aim to modify disease progression and improve neurological outcomes across MSA stages.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Multiple system atrophy (MSA) is a rare and progressive neurodegenerative disorder that affects the autonomic nervous system, motor function, and balance. Multiple system atrophy symptoms manifests through a combination of parkinsonism, autonomic dysfunction, and cerebellar ataxia, making it distinct from Parkinson\u2019s disease despite overlapping symptoms. Unlike Parkinson\u2019s, MSA progresses rapidly, and available treatments focus mainly [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":30885,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[20778,20780,20782,20779,20781],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-30883","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-multiple-system-atrophy","tag-multiple-system-atrophy-market","tag-multiple-system-atrophy-patients","tag-multiple-system-atrophy-treatment","tag-multiple-system-atrophy-treatment-market","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Next Era of Multiple System Atrophy Treatment<\/title>\n<meta name=\"description\" content=\"Future of multiple system atrophy treatment is poised for transformation, driven by increasing recognition of disease-modifying therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Next Era of Multiple System Atrophy Treatment\" \/>\n<meta property=\"og:description\" content=\"Future of multiple system atrophy treatment is poised for transformation, driven by increasing recognition of disease-modifying therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-22T13:33:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T12:12:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27160838\/future-of-multiple-system-atrophy-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Next Era of Multiple System Atrophy Treatment","description":"Future of multiple system atrophy treatment is poised for transformation, driven by increasing recognition of disease-modifying therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment","og_locale":"en_US","og_type":"article","og_title":"Next Era of Multiple System Atrophy Treatment","og_description":"Future of multiple system atrophy treatment is poised for transformation, driven by increasing recognition of disease-modifying therapies.","og_url":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-09-22T13:33:59+00:00","article_modified_time":"2026-03-20T12:12:32+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27160838\/future-of-multiple-system-atrophy-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment","url":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment","name":"Next Era of Multiple System Atrophy Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27160838\/future-of-multiple-system-atrophy-treatment.png","datePublished":"2025-09-22T13:33:59+00:00","dateModified":"2026-03-20T12:12:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Future of multiple system atrophy treatment is poised for transformation, driven by increasing recognition of disease-modifying therapies.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479279647"},{"@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479289074"},{"@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479303962"},{"@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479314436"},{"@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1758540797101"},{"@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1758540811989"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27160838\/future-of-multiple-system-atrophy-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27160838\/future-of-multiple-system-atrophy-treatment.png","width":466,"height":284,"caption":"future-of-multiple-system-atrophy-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479279647","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479279647","name":"What is Multiple System Atrophy (MSA)disease?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"MSA is a rare, progressive neurodegenerative disorder that affects the autonomic nervous system, motor function, and balance. It triggers symptoms such as parkinsonism (rigidity, tremors), cerebellar ataxia (coordination and balance problems), and autonomic dysfunction (orthostatic hypotension, bladder, and bowel issues).","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479289074","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479289074","name":"What causes MSA?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"MSA is caused by abnormal accumulation of alpha-synuclein in oligodendrocytes, leading to neuronal degeneration across the brain and spinal cord. Its exact cause remains unclear, but it is considered multifactorial, involving a combination of genetic susceptibility, environmental triggers, and cellular mechanisms that disrupt normal brain function.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479303962","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479303962","name":"How many stages of MSA are there?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"MSA progresses through five stages, from early mild symptoms (Stage 1) to severe disability (Stage 5). Stages 3 and 4 account for the majority of patients, marked by significant motor impairment, autonomic dysfunction, and increased dependency. Understanding disease stage is critical for treatment selection and prognosis assessment.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479314436","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1757479314436","name":"What are the first signs of MSA?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Early signs of MSA include autonomic dysfunction, such as low blood pressure when standing, urinary incontinence, or erectile dysfunction. Motor symptoms like rigidity, slowness, tremors, and gait instability may also appear. Cerebellar signs like balance problems or coordination difficulties can be early indicators, especially in the MSA-C subtype.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1758540797101","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1758540797101","name":"Is MSA hereditary?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"MSA is generally considered a sporadic condition, meaning it typically occurs without a family history. Rare familial cases have been reported, suggesting some genetic predisposition may exist. However, inherited patterns are uncommon, and most patients develop the disease due to complex interactions between genetic and environmental factors rather than direct inheritance.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1758540811989","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/future-of-multiple-system-atrophy-treatment#faq-question-1758540811989","name":"How is MSA treated?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Treatment focuses on symptom management, as no disease-modifying therapy is approved. Levodopa may relieve parkinsonian symptoms, physiotherapy supports mobility, and adrenergic agents like midodrine or droxidopa address orthostatic hypotension. Emerging therapies, such as ATH434 and ampreloxetine, aim to modify disease progression and improve neurological outcomes across MSA stages.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27160838\/future-of-multiple-system-atrophy-treatment-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy Patients<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Multiple System Atrophy<\/span>","<span class=\"advgb-post-tax-term\">Multiple System Atrophy Market<\/span>","<span class=\"advgb-post-tax-term\">Multiple System Atrophy Patients<\/span>","<span class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment<\/span>","<span class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 months ago","modified":"Updated 1 month ago"},"absolute_dates":{"created":"Posted on Sep 22, 2025","modified":"Updated on Mar 20, 2026"},"absolute_dates_time":{"created":"Posted on Sep 22, 2025 7:03 pm","modified":"Updated on Mar 20, 2026 5:42 pm"},"featured_img_caption":"future-of-multiple-system-atrophy-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30883"}],"version-history":[{"count":6,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30883\/revisions"}],"predecessor-version":[{"id":34789,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30883\/revisions\/34789"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30885"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30883"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30883"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}